Attached files
| file | filename |
|---|---|
| 10-Q - ONCOVISTA INNOVATIVE THERAPIES, INC | v166214_10q.htm |
| EX-31.1 - ONCOVISTA INNOVATIVE THERAPIES, INC | v166214_ex31-1.htm |
CERTIFICATION
PURSUANT TO
18 U.S.C.
SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report on Form 10-Q of OncoVista Innovative
Therapies, Inc. (the "Company") for the period ended September 30, 2009 filed
with the Securities and Exchange Commission (the "Report"), I, Alexander L.
Weis, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:
(1) The
Report fully complies with the requirements of Section 13(a) of the Securities
Exchange Act of 1934; and
(2)
The information contained in the Report
fairly presents, in all material respects, the
consolidated financial condition of the Company as of the
dates presented and consolidated results of operations of the Company
for the periods presented.
Dated:
November 13, 2009
By:
/s/ Alexander L.
Weis, Ph.D.
Alexander
L. Weis, Ph.D.
Chief
Executive and Financial Officer
This
certification has been furnished solely pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
A signed
original of this written statement required by Section 906 has been provided to
OncoVista Innovative Therapies, Inc. and will be retained OncoVista Innovative
Therapies, Inc. and furnished to the Securities and Exchange Commission or its
staff upon request.